HCA Healthcare Reports Third Quarter 2024 Results
Key third quarter metrics (all percentage changes compare 3Q 2024 to 3Q 2023 unless otherwise noted):
-
Revenues totaled
$17.487 billion -
Net income attributable to
HCA Healthcare, Inc. totaled$1.270 billion , or$4.88 per diluted share (which includes an estimated$0.15 per diluted share unfavorable impact from Hurricane Helene) -
Adjusted EBITDA totaled
$3.267 billion -
Cash flows from operating activities totaled
$3.515 billion - Same facility admissions increased 4.5 percent and same facility equivalent admissions increased 4.5 percent
“Our people recently, and heroically, responded to two major hurricanes in less than two weeks. The teamwork and enterprise capabilities of
Revenues in the third quarter of 2024 totaled
For the third quarter of 2024, Adjusted EBITDA totaled
The third quarter of 2023 included revenues of
Same facility admissions increased 4.5 percent and same facility equivalent admissions increased 4.5 percent in the third quarter of 2024, compared to the prior year period. Same facility emergency room visits increased 4.6 percent in the third quarter of 2024, compared to the prior year period. Same facility inpatient surgeries increased 1.6 percent, and same facility outpatient surgeries declined 2.0 percent in the third quarter of 2024, compared to the same period of 2023. Same facility revenue per equivalent admission increased 2.5 percent in the third quarter of 2024, compared to the third quarter of 2023.
Nine Months Ended
Revenues for the nine months ended
Impact of Hurricanes
During the third quarter of 2024, the Company incurred additional expenses and experienced loss of revenues estimated at
During the fourth quarter of 2024, the Company anticipates ongoing additional expenses and loss of revenues due to Hurricane Helene’s impact on its
2024 Guidance
Today, the Company reaffirmed its 2024 estimated guidance ranges. Given the ongoing impact of the two major hurricanes on the remainder of the year, the Company estimates that results are likely to be in the lower half of the ranges provided.
Capital expenditures for 2024, excluding acquisitions, are now estimated to be approximately
The Company’s guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payor mix, and the ongoing impacts of the two major hurricanes, as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to
The Company’s 2024 guidance and initial 2025 outlook that follows are based on current plans and expectations and are subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
Initial 2025 Outlook
While the Company anticipates some ongoing impact in 2025 from Hurricane Helene on its
Balance Sheet and Cash Flows from Operations
As of
During the third quarter of 2024, the Company repurchased 4.948 million shares of its common stock at a cost of
Dividend
HCA today announced that its Board of Directors declared a quarterly cash dividend of
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.
Earnings Conference Call
About the Company
As of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending
Condensed Consolidated Comprehensive Income Statements Third Quarter Unaudited (Dollars in millions, except per share amounts) |
|||||||||||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
||||||||||
|
|
|
Amount |
|
|
Ratio |
|
|
|
Amount |
|
|
Ratio |
|
|
||||
Revenues |
|
|
$ |
17,487 |
|
|
|
100.0 |
|
% |
|
$ |
16,213 |
|
|
|
100.0 |
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Salaries and benefits |
|
|
|
7,861 |
|
|
|
45.0 |
|
|
|
|
7,556 |
|
|
|
46.6 |
|
|
Supplies |
|
|
|
2,657 |
|
|
|
15.2 |
|
|
|
|
2,417 |
|
|
|
14.9 |
|
|
Other operating expenses |
|
|
|
3,717 |
|
|
|
21.2 |
|
|
|
|
3,379 |
|
|
|
20.8 |
|
|
Equity in earnings of affiliates |
|
|
|
(15 |
) |
|
|
(0.1 |
) |
|
|
|
(19 |
) |
|
|
(0.1 |
) |
|
Depreciation and amortization |
|
|
|
842 |
|
|
|
4.9 |
|
|
|
|
769 |
|
|
|
4.7 |
|
|
Interest expense |
|
|
|
515 |
|
|
|
2.9 |
|
|
|
|
483 |
|
|
|
3.0 |
|
|
Losses (gains) on sales of facilities |
|
|
|
4 |
|
|
|
— |
|
|
|
|
(2 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
15,581 |
|
|
|
89.1 |
|
|
|
|
14,583 |
|
|
|
89.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income before income taxes |
|
|
|
1,906 |
|
|
|
10.9 |
|
|
|
|
1,630 |
|
|
|
10.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Provision for income taxes |
|
|
|
424 |
|
|
|
2.4 |
|
|
|
|
355 |
|
|
|
2.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income |
|
|
|
1,482 |
|
|
|
8.5 |
|
|
|
|
1,275 |
|
|
|
7.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to noncontrolling interests |
|
|
|
212 |
|
|
|
1.2 |
|
|
|
|
196 |
|
|
|
1.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to |
|
|
$ |
1,270 |
|
|
|
7.3 |
|
|
|
$ |
1,079 |
|
|
|
6.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted earnings per share |
|
|
$ |
4.88 |
|
|
|
|
|
|
$ |
3.91 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Shares used in computing diluted earnings per share (millions) |
|
|
|
259.917 |
|
|
|
|
|
|
|
275.424 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive income attributable to |
$ |
1,325 |
$ |
1,044 |
Condensed Consolidated Comprehensive Income Statements
For the Nine Months Ended Unaudited (Dollars in millions, except per share amounts) |
||||||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
||||||||||
|
|
Amount |
|
|
Ratio |
|
|
|
Amount |
|
|
Ratio |
|
|
||||
Revenues |
|
$ |
52,318 |
|
|
|
100.0 |
|
% |
|
$ |
47,665 |
|
|
|
100.0 |
|
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Salaries and benefits |
|
|
23,253 |
|
|
|
44.4 |
|
|
|
|
21,917 |
|
|
|
46.0 |
|
|
Supplies |
|
|
7,962 |
|
|
|
15.2 |
|
|
|
|
7,318 |
|
|
|
15.4 |
|
|
Other operating expenses |
|
|
10,946 |
|
|
|
21.0 |
|
|
|
|
9,316 |
|
|
|
19.5 |
|
|
Equity in (earnings) losses of affiliates |
|
|
(13 |
) |
|
|
— |
|
|
|
|
6 |
|
|
|
— |
|
|
Depreciation and amortization |
|
|
2,456 |
|
|
|
4.7 |
|
|
|
|
2,288 |
|
|
|
4.9 |
|
|
Interest expense |
|
|
1,533 |
|
|
|
2.9 |
|
|
|
|
1,447 |
|
|
|
3.0 |
|
|
Losses (gains) on sales of facilities |
|
|
(209 |
) |
|
|
(0.4 |
) |
|
|
|
12 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
45,928 |
|
|
|
87.8 |
|
|
|
|
42,304 |
|
|
|
88.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income before income taxes |
|
|
6,390 |
|
|
|
12.2 |
|
|
|
|
5,361 |
|
|
|
11.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Provision for income taxes |
|
|
1,419 |
|
|
|
2.7 |
|
|
|
|
1,131 |
|
|
|
2.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income |
|
|
4,971 |
|
|
|
9.5 |
|
|
|
|
4,230 |
|
|
|
8.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to noncontrolling interests |
|
|
649 |
|
|
|
1.2 |
|
|
|
|
595 |
|
|
|
1.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to |
|
$ |
4,322 |
|
|
|
8.3 |
|
|
|
$ |
3,635 |
|
|
|
7.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted earnings per share |
|
$ |
16.37 |
|
|
|
|
|
|
$ |
13.07 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Shares used in computing diluted earnings per share (millions) |
|
|
263.987 |
|
|
|
|
|
|
|
278.173 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive income attributable to |
$ |
4,369 |
$ |
3,634 |
Condensed Consolidated Balance Sheets Unaudited (Dollars in millions) |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|||
|
|
2024 |
|
|
2024 |
|
|
2023 |
|
|||
ASSETS |
|
|
|
|
|
|
|
|
|
|||
Current assets: |
|
|
|
|
|
|
|
|
|
|||
Cash and cash equivalents |
|
$ |
2,888 |
|
|
$ |
831 |
|
|
$ |
935 |
|
Accounts receivable |
|
|
9,915 |
|
|
|
10,239 |
|
|
|
9,958 |
|
Inventories |
|
|
1,776 |
|
|
|
1,800 |
|
|
|
2,021 |
|
Other |
|
|
2,083 |
|
|
|
2,303 |
|
|
|
2,013 |
|
|
|
|
16,662 |
|
|
|
15,173 |
|
|
|
14,927 |
|
|
|
|
|
|
|
|
|
|
|
|||
Property and equipment, at cost |
|
|
61,750 |
|
|
|
60,625 |
|
|
|
58,548 |
|
Accumulated depreciation |
|
|
(32,703 |
) |
|
|
(31,986 |
) |
|
|
(30,833 |
) |
|
|
|
29,047 |
|
|
|
28,639 |
|
|
|
27,715 |
|
|
|
|
|
|
|
|
|
|
|
|||
Investments of insurance subsidiaries |
|
|
553 |
|
|
|
483 |
|
|
|
477 |
|
Investments in and advances to affiliates |
|
|
705 |
|
|
|
702 |
|
|
|
756 |
|
|
|
|
9,982 |
|
|
|
9,963 |
|
|
|
9,945 |
|
Right-of-use operating lease assets |
|
|
2,201 |
|
|
|
2,179 |
|
|
|
2,207 |
|
Other |
|
|
309 |
|
|
|
240 |
|
|
|
184 |
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
$ |
59,459 |
|
|
$ |
57,379 |
|
|
$ |
56,211 |
|
|
|
|
|
|
|
|
|
|
|
|||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|||
Current liabilities: |
|
|
|
|
|
|
|
|
|
|||
Accounts payable |
|
$ |
4,235 |
|
|
$ |
4,029 |
|
|
$ |
4,233 |
|
Accrued salaries |
|
|
2,164 |
|
|
|
1,993 |
|
|
|
2,127 |
|
Other accrued expenses |
|
|
3,819 |
|
|
|
3,705 |
|
|
|
3,871 |
|
Long-term debt due within one year |
|
|
4,682 |
|
|
|
4,574 |
|
|
|
2,424 |
|
|
|
|
14,900 |
|
|
|
14,301 |
|
|
|
12,655 |
|
|
|
|
|
|
|
|
|
|
|
|||
Long-term debt, less debt issuance costs and discounts of |
|
|
38,283 |
|
|
|
36,306 |
|
|
|
37,169 |
|
Professional liability risks |
|
|
1,584 |
|
|
|
1,573 |
|
|
|
1,557 |
|
Right-of-use operating lease obligations |
|
|
1,924 |
|
|
|
1,894 |
|
|
|
1,903 |
|
Income taxes and other liabilities |
|
|
1,982 |
|
|
|
1,966 |
|
|
|
1,867 |
|
|
|
|
|
|
|
|
|
|
|
|||
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
|||
Stockholders' deficit attributable to |
|
|
(2,182 |
) |
|
|
(1,600 |
) |
|
|
(1,774 |
) |
Noncontrolling interests |
|
|
2,968 |
|
|
|
2,939 |
|
|
|
2,834 |
|
|
|
|
786 |
|
|
|
1,339 |
|
|
|
1,060 |
|
|
|
$ |
59,459 |
|
$ |
57,379 |
$ |
56,211 |
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended Unaudited (Dollars in millions) |
||||||||
|
|
2024 |
|
|
2023 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net income |
|
$ |
4,971 |
|
|
$ |
4,230 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
||
Increase (decrease) in cash from operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
55 |
|
|
|
(168 |
) |
Inventories and other assets |
|
|
184 |
|
|
|
(274 |
) |
Accounts payable and accrued expenses |
|
|
77 |
|
|
|
211 |
|
Depreciation and amortization |
|
|
2,456 |
|
|
|
2,288 |
|
Income taxes |
|
|
(67 |
) |
|
|
61 |
|
Losses (gains) on sales of facilities |
|
|
(209 |
) |
|
|
12 |
|
Amortization of debt issuance costs and discounts |
|
|
26 |
|
|
|
26 |
|
Share-based compensation |
|
|
275 |
|
|
|
205 |
|
Other |
|
|
187 |
|
|
|
166 |
|
|
|
|
|
|
|
|
||
Net cash provided by operating activities |
|
|
7,955 |
|
|
|
6,757 |
|
|
|
|
|
|
|
|
||
Cash flows from investing activities: |
|
|
|
|
|
|
||
Purchase of property and equipment |
|
|
(3,590 |
) |
|
|
(3,585 |
) |
Acquisition of hospitals and health care entities |
|
|
(224 |
) |
|
|
(281 |
) |
Sales of hospitals and health care entities |
|
|
312 |
|
|
|
183 |
|
Change in investments |
|
|
(85 |
) |
|
|
(30 |
) |
Other |
|
|
- |
|
|
|
(7 |
) |
|
|
|
|
|
|
|
||
Net cash used in investing activities |
|
|
(3,587 |
) |
|
|
(3,720 |
) |
|
|
|
|
|
|
|
||
Cash flows from financing activities: |
|
|
|
|
|
|
||
Issuances of long-term debt |
|
|
7,495 |
|
|
|
3,220 |
|
Net change in revolving credit facilities |
|
|
(1,880 |
) |
|
|
(1,420 |
) |
Repayment of long-term debt |
|
|
(2,346 |
) |
|
|
(691 |
) |
Distributions to noncontrolling interests |
|
|
(530 |
) |
|
|
(497 |
) |
Payment of debt issuance costs |
|
|
(67 |
) |
|
|
(31 |
) |
Payment of dividends |
|
|
(525 |
) |
|
|
(501 |
) |
Repurchase of common stock |
|
|
(4,342 |
) |
|
|
(2,901 |
) |
Other |
|
|
(224 |
) |
|
|
(234 |
) |
|
|
|
|
|
|
|
||
Net cash used in financing activities |
|
|
(2,419 |
) |
|
|
(3,055 |
) |
|
|
|
|
|
|
|
||
Effect of exchange rate changes on cash and cash equivalents |
|
|
4 |
|
|
|
1 |
|
|
|
|
|
|
|
|
||
Change in cash and cash equivalents |
|
|
1,953 |
|
|
|
(17 |
) |
Cash and cash equivalents at beginning of period |
|
|
935 |
|
|
|
908 |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents at end of period |
|
$ |
2,888 |
|
|
$ |
891 |
|
|
|
|
|
|
|
|
||
Interest payments |
|
$ |
1,405 |
|
|
$ |
1,460 |
|
Income tax payments, net |
|
$ |
1,486 |
|
|
$ |
1,070 |
|
Operating Statistics |
||||||||||||||||
|
|
Third Quarter |
|
|
For the Nine Months
|
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Number of Hospitals |
|
|
187 |
|
|
|
183 |
|
|
|
187 |
|
|
|
183 |
|
Number of Freestanding Outpatient Surgery Centers* |
|
|
125 |
|
|
|
126 |
|
|
|
125 |
|
|
|
126 |
|
Licensed Beds at End of Period |
|
|
49,890 |
|
|
|
49,279 |
|
|
|
49,890 |
|
|
|
49,279 |
|
Weighted Average Beds in Service |
|
|
42,640 |
|
|
|
41,927 |
|
|
|
42,609 |
|
|
|
41,805 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Reported: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Admissions |
|
|
562,100 |
|
|
|
537,943 |
|
|
|
1,677,425 |
|
|
|
1,586,174 |
|
% Change |
|
|
4.5 |
% |
|
|
|
|
|
5.8 |
% |
|
|
|
||
Equivalent Admissions |
|
|
1,006,106 |
|
|
|
958,504 |
|
|
|
2,982,462 |
|
|
|
2,813,873 |
|
% Change |
|
|
5.0 |
% |
|
|
|
|
|
6.0 |
% |
|
|
|
||
Revenue per Equivalent Admission |
|
$ |
17,381 |
|
|
$ |
16,915 |
|
|
$ |
17,542 |
|
|
$ |
16,939 |
|
% Change |
|
|
2.8 |
% |
|
|
|
|
|
3.6 |
% |
|
|
|
||
Inpatient Revenue per Admission |
|
$ |
18,728 |
|
|
$ |
18,262 |
|
|
$ |
18,822 |
|
|
$ |
17,930 |
|
% Change |
|
|
2.6 |
% |
|
|
|
|
|
5.0 |
% |
|
|
|
||
|
|
|
2,690,718 |
|
|
|
2,612,439 |
|
|
|
8,134,864 |
|
|
|
7,808,905 |
|
% Change |
|
|
3.0 |
% |
|
|
|
|
|
4.2 |
% |
|
|
|
||
Equivalent |
|
|
4,816,761 |
|
|
|
4,655,252 |
|
|
|
14,463,788 |
|
|
|
13,852,997 |
|
% Change |
|
|
3.5 |
% |
|
|
|
|
|
4.4 |
% |
|
|
|
||
Inpatient Surgery Cases |
|
|
135,803 |
|
|
|
133,521 |
|
|
|
405,061 |
|
|
|
396,428 |
|
% Change |
|
|
1.7 |
% |
|
|
|
|
|
2.2 |
% |
|
|
|
||
Outpatient Surgery Cases |
|
|
249,364 |
|
|
|
254,557 |
|
|
|
761,166 |
|
|
|
774,129 |
|
% Change |
|
|
-2.0 |
% |
|
|
|
|
|
-1.7 |
% |
|
|
|
||
Emergency Room Visits |
|
|
2,446,962 |
|
|
|
2,343,514 |
|
|
|
7,290,836 |
|
|
|
6,890,388 |
|
% Change |
|
|
4.4 |
% |
|
|
|
|
|
5.8 |
% |
|
|
|
||
Outpatient Revenues as a Percentage of Patient Revenues |
|
|
38.2 |
% |
|
|
37.4 |
% |
|
|
37.8 |
% |
|
|
38.3 |
% |
Average Length of Stay (days) |
|
|
4.787 |
|
|
|
4.856 |
|
|
|
4.850 |
|
|
|
4.923 |
|
Occupancy** |
|
|
71.9 |
% |
|
|
71.4 |
% |
|
|
73.0 |
% |
|
|
72.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Same Facility: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Admissions |
|
|
558,105 |
|
|
|
534,323 |
|
|
|
1,663,509 |
|
|
|
1,577,063 |
|
% Change |
|
|
4.5 |
% |
|
|
|
|
|
5.5 |
% |
|
|
|
||
Equivalent Admissions |
|
|
985,613 |
|
|
|
943,614 |
|
|
|
2,919,458 |
|
|
|
2,781,939 |
|
% Change |
|
|
4.5 |
% |
|
|
|
|
|
4.9 |
% |
|
|
|
||
Revenue per Equivalent Admission |
|
$ |
17,311 |
|
|
$ |
16,887 |
|
|
$ |
17,468 |
|
|
$ |
16,882 |
|
% Change |
|
|
2.5 |
% |
|
|
|
|
|
3.5 |
% |
|
|
|
||
Inpatient Revenue per Admission |
|
$ |
18,793 |
|
|
$ |
18,214 |
|
|
$ |
18,873 |
|
|
$ |
17,917 |
|
% Change |
|
|
3.2 |
% |
|
|
|
|
|
5.3 |
% |
|
|
|
||
Inpatient Surgery Cases |
|
|
134,913 |
|
|
|
132,793 |
|
|
|
402,150 |
|
|
|
394,377 |
|
% Change |
|
|
1.6 |
% |
|
|
|
|
|
2.0 |
% |
|
|
|
||
Outpatient Surgery Cases |
|
|
244,733 |
|
|
|
249,753 |
|
|
|
746,717 |
|
|
|
762,328 |
|
% Change |
|
|
-2.0 |
% |
|
|
|
|
|
-2.0 |
% |
|
|
|
||
Emergency Room Visits |
|
|
2,433,887 |
|
|
|
2,325,946 |
|
|
|
7,232,588 |
|
|
|
6,839,030 |
|
% Change |
|
|
4.6 |
% |
|
|
|
|
|
5.8 |
% |
|
|
|
||
* Excludes freestanding endoscopy centers (23 centers at ** Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service. |
Supplemental Non-GAAP Disclosures Operating Results Summary (Dollars in millions, except per share amounts) |
||||||||||||||||
|
|
Third Quarter |
|
|
For the Nine Months
|
|
||||||||||
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Revenues |
|
$ |
17,487 |
|
|
$ |
16,213 |
|
|
$ |
52,318 |
|
|
$ |
47,665 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to |
|
$ |
1,270 |
|
|
$ |
1,079 |
|
|
$ |
4,322 |
|
|
$ |
3,635 |
|
Losses (gains) on sales of facilities (net of tax) |
|
|
3 |
|
|
|
(1 |
) |
|
|
(160 |
) |
|
|
21 |
|
Net income attributable to |
|
|
1,273 |
|
|
|
1,078 |
|
|
|
4,162 |
|
|
|
3,656 |
|
Depreciation and amortization |
|
|
842 |
|
|
|
769 |
|
|
|
2,456 |
|
|
|
2,288 |
|
Interest expense |
|
|
515 |
|
|
|
483 |
|
|
|
1,533 |
|
|
|
1,447 |
|
Provision for income taxes |
|
|
425 |
|
|
|
354 |
|
|
|
1,370 |
|
|
|
1,122 |
|
Net income attributable to noncontrolling interests |
|
|
212 |
|
|
|
196 |
|
|
|
649 |
|
|
|
595 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjusted EBITDA (a) |
|
|
3,267 |
|
|
$ |
2,880 |
|
|
$ |
10,170 |
|
|
$ |
9,108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjusted EBITDA margin (a) |
|
|
18.7 |
% |
|
|
17.8 |
% |
|
|
19.4 |
% |
|
|
19.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income attributable to |
|
$ |
4.88 |
|
|
$ |
3.91 |
|
|
$ |
16.37 |
|
|
$ |
13.07 |
|
Losses (gains) on sales of facilities |
|
|
0.02 |
|
|
|
- |
|
|
|
(0.61 |
) |
|
|
0.07 |
|
Net income attributable to |
|
$ |
4.90 |
|
|
$ |
3.91 |
|
|
$ |
15.76 |
|
|
$ |
13.14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Shares used in computing diluted earnings per share (millions) |
|
|
259.917 |
|
|
|
275.424 |
|
|
|
263.987 |
|
|
|
278.173 |
|
_____________________ | ||||||||||||||||||
(a) |
Net income attributable to |
|||||||||||||||||
Management and investors review both the overall performance (including net income attributable to |
||||||||||||||||||
Net income attributable to |
Supplemental Non-GAAP Disclosures 2024 Operating Results Forecast (Dollars in millions, except per share amounts) |
||||||||
|
|
For the Year Ending |
|
|||||
|
|
|
|
|||||
|
|
Low |
|
|
High |
|
||
Revenues |
|
$ |
69,750 |
|
|
$ |
71,750 |
|
|
|
|
|
|
|
|
||
Net income attributable to |
|
$ |
5,675 |
|
|
$ |
5,975 |
|
Depreciation and amortization |
|
|
3,245 |
|
|
|
3,295 |
|
Interest expense |
|
|
2,065 |
|
|
|
2,095 |
|
Provision for income taxes |
|
|
1,860 |
|
|
|
1,950 |
|
Net income attributable to noncontrolling interests |
|
|
905 |
|
|
|
935 |
|
|
|
|
|
|
|
|
||
Adjusted EBITDA (a) (b) |
|
$ |
13,750 |
|
|
$ |
14,250 |
|
|
|
|
|
|
|
|
||
Diluted earnings per share: |
|
|
|
|
|
|
||
Net income attributable to |
|
$ |
21.60 |
|
|
$ |
22.80 |
|
|
|
|
|
|
|
|
||
Shares used in computing diluted earnings per share (millions) |
|
|
262.000 |
|
|
|
262.000 |
|
The Company's forecasted guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks. | ||||||||
_________________________ | ||||||||
(a) | The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. | |||||||
(b) |
Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. |
|||||||
Management and investors review both the overall performance (including net income attributable to |
||||||||
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241025897327/en/
INVESTOR CONTACT:
615-344-2688
MEDIA CONTACT:
615-344-1851
Source: